Menopause Review
facebook
eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Online First About the journal Editorial board Abstracting and indexing Subscription Contact Ethical standards and procedures Special Issues Instructions for authors Publication charge
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
Share:
Send email
Share:
Original paper

Estrogen receptor status low status in breast cancer: clinicopathological factors and prognostic value

Joanna Huszno
1
,
Zofia Kołosza
2
,
Ewa Stobiecka
3
,
Dorota Ponikiewska
3
,
Bogna Szcześniak
3
,
Jakub Simek
3
,
Ewa Chmielik
3

  1. Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
  2. Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
  3. Tumor Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
Menopause Rev 2026; 25(1): 1-6
DOI: https://doi.org/10.5114/pm.2026.161538
Online publish date: 2026/05/06
Article file
- 00986 Estrogen receptor status.pdf  [0.21 MB]
Get citation
 
PlumX metrics:
 
1. Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 2023; 34: 645-659.
2. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 2020; 38: 1346-1366.
3. Poon IK, Tsang JY, Li J, Chan SK, Shea KH, Tse GM. The significance of highlighting the oestrogen receptor low category in breast cancer. Br J Cancer 2020; 123: 1223-1227.
4. Reinert T, Cascelli F, de Resende CAA, Gonçalves AC, Godo VSP, Barrios CH. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer. Front Endocrinol (Lausanne) 2022; 13: 1015388.
5. Fei F, Siegal GP, Wei S. Characterization of estrogen receptor-low-positive breast cancer. Breast Cancer Res Treat 2021; 188: 225-235.
6. Yoon KH, Park Y, Kang E, Kim EK, Kim JH, Kim SH, et al. Effect of estrogen receptor expression level and hormonal therapy on prognosis of early breast cancer. Cancer Res Treat 2022; 54: 1081-1090.
7. Luo C, Zhong X, Fan Y, Wu Y, Zheng H, Luo T. Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer. Breast 2022; 63: 24-28.
8. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol 2014; 25: 1004-1011.
9. Kim MC, Park MH, Choi JE, Kang SH, Bae YK. Characteristics and prognosis of estrogen receptor low-positive breast cancer. J Breast Cancer 2022; 25: 318-326.
10. Skjervold AH, Valla M, Bofin AM. Oestrogen receptor low positive breast cancer: associations with prognosis. Breast Cancer Res Treat 2023; 201: 535-545.
11. Malainou CP, Stachika N, Damianou AK, Anastopoulos A, Ploumaki I, Triantafyllou E, et al. Estrogen-receptor-low-positive breast cancer: pathological and clinical PerspectKotteasives. Curr Oncol 2023; 30: 9734-9745.
12. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, et al. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer 2015; 121: 3422-3427.
13. Yu KD, Cai YW, Wu SY, Shui RH, Shao ZM. Estrogen receptor-low breast cancer: biology chaos and treatment paradox. Cancer Commun (Lond) 2021; 41: 968-980.
14. Ivanova M, Porta FM, D’Ercole M, Pescia C, Sajjadi E, Cursano G, et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch 2024; 484: 3-14.
15. Schrodi S, Braun M, Andrulat A, Harbeck N, Mahner S, Kiechle M, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol 2021; 32: 1410-1424.
16. Park YH, Karantza V, Calhoun SR, Park S, Lee S, Kim JY,  et al. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea. Breast Cancer Res Treat 2021; 189: 653-663.
17. Paakkola NM, Karakatsanis A, Mauri D, Foukakis T, Valachis A. The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis. ESMO Open 2021; 6: 100289.
18. Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – an analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148: 159-170.
19. Da Silva JL, da Silva LFL, Schwengber WK, Zanetti de Albuquerque L, Cardoso Nunes NC, de Melo AC. Evaluating the efficacy and safety of NEOadjuvant CHEmoimmunotherapy in early ER-low/HER2-negative breast cancer (NEOCHEER): a systematic review and meta-analysis. Clin Breast Cancer 2025; 26: 296-303.
20. Gavino F, Eleonora L, Pina Z, Pretta A, Tiwari E, Dessì M,  et al. Estrogen receptor-low positive (ER-Low) breast cancer: a unique clinical and pathological entity. Curr Oncol 2026; 33: 122
21. Im S.A. Lee K.H. Min A, LeeD, Kim TY, Ryu HS, et al. Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer. Cancer Res 2022; 82: PD15-08.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.